All Stories

  1. Data from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

    Article • September 2024, American Association for Cancer Research (AACR)

    Laia Pare

  2. Data from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

    Article • September 2024, American Association for Cancer Research (AACR)

    Laia Pare

  3. Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

    Article • September 2024, American Association for Cancer Research (AACR)

    Laia Pare

  4. Supplementary Data1 from HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

    Article • September 2024, American Association for Cancer Research (AACR)

    Laia Pare

  5. HER2DX Genomic Assay in HER2-Positive Early Breast Cancer Treated with Trastuzumab and Pertuzumab: A Correlative Analysis from the PHERGain Phase II Trial

    Article • Clinical Cancer Research, July 2024, American Association for Cancer Research (AACR)

    Laia Pare

  6. Cell-cycle inhibition and immune microenvironment in breast cancer treated with ribociclib and letrozole or chemotherapy

    Article • npj Breast Cancer, March 2024, Springer Science + Business Media

    Laia Pare

  7. Metastatic site patterns by intrinsic subtype and HER2DX in early HER2-positive breast cancer

    Article • JNCI Journal of the National Cancer Institute, September 2023, Oxford University Press (OUP)

    Laia Pare

  8. Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

    Article • Annals of Oncology, September 2023, Elsevier

    Laia Pare

  9. Patritumab deruxtecan in untreated hormone receptor-positive/HER2-negative early breast cancer: final results from part A of the window-of-opportunity SOLTI TOT-HER3 pre-operative study

    Article • Annals of Oncology, August 2023, Elsevier

    Laia Pare

  10. Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

    Article • JAMA Oncology, June 2023, American Medical Association (AMA)

    Laia Pare

  11. Assessment of the HER2DX Assay in Patients With ERBB2-Positive Breast Cancer Treated With Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab

    Article • JAMA Oncology, June 2023, American Medical Association (AMA)

    Laia Pare

  12. Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis

    Article • ESMO Open, June 2023, Elsevier

    Laia Pare

  13. Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Article • npj Breast Cancer, April 2023, Springer Science + Business Media

    Laia Pare

  14. Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer

    Article • JAMA Oncology, April 2023, American Medical Association (AMA)

    Laia Pare

  15. Supplementary Data from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  16. Supplementary Data from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  17. Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  18. Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  19. Supplementary Figure from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  20. Data from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  21. Supplementary Table from De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • April 2023, American Association for Cancer Research (AACR)

    Laia Pare

  22. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

    Article • Nature Communications, March 2023, Springer Science + Business Media

    Laia Pare

  23. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

    Article • The Lancet Oncology, March 2023, Elsevier

    Laia Pare

  24. HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1

    Article • JNCI Journal of the National Cancer Institute, December 2022, Oxford University Press (OUP)

    Laia Pare

  25. De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial

    Article • Clinical Cancer Research, July 2022, American Association for Cancer Research (AACR)

    Laia Pare

  26. Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer

    Article • EBioMedicine, January 2022, Elsevier

    Laia Pare

  27. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

    Article • npj Breast Cancer, November 2021, Springer Science + Business Media

    Laia Pare

  28. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease

    Article • Frontiers in Immunology, November 2021, Frontiers

    Laia Pare

  29. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    Article • Frontiers in Oncology, November 2021, Frontiers

    Laia Pare

  30. Gene expression profiles of breast cancer metastasis according to organ site

    Article • Molecular Oncology, June 2021, Wiley

    Laia Pare

  31. The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers

    Article • npj Breast Cancer, June 2021, Springer Science + Business Media

    Laia Pare

  32. Identification of cell surface targets for CAR-T cell therapies and antibody–drug conjugates in breast cancer

    Article • ESMO Open, June 2021, Elsevier

    Laia Pare

  33. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    Laia Pare

  34. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer

    Article • European Journal of Cancer, May 2021, Elsevier

    Laia Pare

  35. SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer

    Article • Frontiers in Oncology, April 2021, Frontiers

    Laia Pare

  36. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    Article • npj Precision Oncology, March 2021, Springer Science + Business Media

    Laia Pare

  37. Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor–Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti–HER2-Based Therapy

    Article • Clinical Cancer Research, February 2021, American Association for Cancer Research (AACR)

    Laia Pare

  38. Immune microenvironment and intrinsic subtyping in hormone receptor-positive/HER2-negative breast cancer

    Article • npj Breast Cancer, February 2021, Springer Science + Business Media

    Laia Pare

  39. Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®

    Article • npj Breast Cancer, February 2021, Springer Science + Business Media

    Laia Pare

  40. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

    Article • npj Breast Cancer, January 2021, Springer Science + Business Media

    Laia Pare

  41. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Article • Breast Cancer Research, November 2020, Springer Science + Business Media

    Laia Pare

  42. A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation

    Article • The Lancet Oncology, November 2020, Elsevier

    Laia Pare

  43. A prognostic model based on PAM50 and clinical variables (PAM50MET) for metastatic hormone-receptor-positive HER2-negative breast cancer

    Article • Clinical Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Laia Pare

  44. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: Results from the phase II SOLTI-1303 PATRICIA trial

    Article • Clinical Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Laia Pare

  45. DNA methylation events in transcription factors and gene expression changes in colon cancer

    Article • Epigenomics, September 2020, Future Medicine

    Laia Pare

  46. PIK3CA mutation in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer: association with prognosis and integration with PAM50 subtype.

    Article • Clinical Cancer Research, August 2020, American Association for Cancer Research (AACR)

    Laia Pare

  47. ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer

    Article • Cancers, July 2020, MDPI AG

    Laia Pare

  48. Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

    Article • Nature Communications, January 2020, Springer Science + Business Media

    Laia Pare

  49. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial

    Article • The Lancet Oncology, January 2020, Elsevier

    Laia Pare

  50. Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    Article • Frontiers in Oncology, September 2019, Frontiers

    Laia Pare

  51. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Article • September 2019, Springer Science + Business Media

    Laia Pare

  52. PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

    Article • Frontiers in Oncology, August 2019, Frontiers

    Laia Pare

  53. The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models

    Article • Molecular Cancer Research, July 2019, American Association for Cancer Research (AACR)

    Laia Pare

  54. Everolimus plus Exemestane for Hormone Receptor‐Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO‐2

    Article • The Oncologist, July 2019, Wiley

    Laia Pare

  55. Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple‐negative early breast cancer: Primary translational analysis of the WSG‐ADAPT‐TN trial

    Article • International Journal of Cancer, June 2019, Wiley

    Laia Pare

  56. Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity

    Article • Cancer Research, June 2019, American Association for Cancer Research (AACR)

    Laia Pare

  57. De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2-week letrozole: results of the PerELISA neoadjuvant study

    Article • Annals of Oncology, June 2019, Elsevier

    Laia Pare

  58. HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade

    Article • JNCI Journal of the National Cancer Institute, April 2019, Oxford University Press (OUP)

    Laia Pare

  59. A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer

    Article • Frontiers in Oncology, April 2019, Frontiers

    Laia Pare

  60. Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial

    Article • BMC Medicine, January 2019, Springer Science + Business Media

    Laia Pare

  61. Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

    Article • Annals of Oncology, October 2018, Elsevier

    Laia Pare

  62. A predictive model of pathologic response based on tumor cellularity and tumor-infiltrating lymphocytes (CelTIL) in HER2-positive breast cancer treated with chemo-free dual HER2 blockade

    Article • Annals of Oncology, January 2018, Elsevier

    Laia Pare

  63. GPR56/ADGRG1 Inhibits Mesenchymal Differentiation and Radioresistance in Glioblastoma

    Article • Cell Reports, November 2017, Elsevier

    Laia Pare

  64. Corrigendum re: “TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer” [Eur Urol 2016;70:709–13]

    Article • European Urology, August 2017, Elsevier

    Laia Pare

  65. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

    Article • Cancer Research, May 2017, American Association for Cancer Research (AACR)

    Laia Pare

  66. Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population

    Article • Stem Cell Reports, May 2017, Elsevier

    Laia Pare

  67. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial

    Article • The Lancet Oncology, April 2017, Elsevier

    Laia Pare

  68. Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer

    Article • Cancer Research, March 2017, American Association for Cancer Research (AACR)

    Laia Pare

  69. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer

    Article • Oncotarget, February 2017, Impact Journals, LLC

    Laia Pare

  70. Identification of ALK , ROS1 , and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non–Small-Cell Lung Cancer ...

    Article • Clinical Chemistry, January 2017, AACC

    Dr Crisitna Teixidó, Fernando Lopez-Rios, Laia Pare

  71. A PAM50-Based Chemoendocrine Score for Hormone Receptor–Positive Breast Cancer with an Intermediate Risk of Relapse

    Article • Clinical Cancer Research, November 2016, American Association for Cancer Research (AACR)

    Laia Pare

  72. TMPRSS2-ERG in Blood and Docetaxel Resistance in Metastatic Castration-resistant Prostate Cancer

    Article • European Urology, November 2016, Elsevier

    Laia Pare

  73. Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib

    Article • JAMA Oncology, October 2016, American Medical Association (AMA)

    Laia Pare

  74. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial

    Article • Annals of Oncology, October 2016, Elsevier

    Laia Pare

  75. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy

    Article • BMC Medicine, December 2015, Springer Science + Business Media

    Laia Pare

  76. Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer

    Article • Bioinformatics, November 2015, Oxford University Press (OUP)

    Dr Benjamin Haibe-Kains, Laia Pare

  77. Epigenetics override pro-inflammatory PTGS transcriptomic signature towards selective hyperactivation of PGE2 in colorectal cancer

    Article • Clinical Epigenetics, July 2015, Springer Science + Business Media

    Lisardo Bosca, Laia Pare

  78. Population-based multicase-control study in common tumors in Spain (MCC-Spain): rationale and study design

    Article • Gaceta Sanitaria, July 2015, Elsevier

    Dr Jesus Almeda, Laia Pare

  79. Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I–III Non–Small-Cell Lung Cancer

    Article • Journal of Thoracic Oncology, July 2015, Elsevier

    Laia Pare

  80. Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer

    Article • Clinical Cancer Research, June 2015, American Association for Cancer Research (AACR)

    Laia Pare

  81. Genetic variations in the VEGF pathway as prognostic factors in metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy

    Article • The Pharmacogenomics Journal, February 2015, Springer Science + Business Media

    Laia Pare

  82. Large differences in global transcriptional regulatory programs of normal and tumor colon cells

    Article • BMC Cancer, September 2014, Springer Science + Business Media

    Laia Pare

  83. Identification of candidate susceptibility genes for colorectal cancer through eQTL analysis

    Article • Carcinogenesis, April 2014, Oxford University Press (OUP)

    Laia Pare

  84. Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer

    Article • Molecular Cancer, January 2014, Springer Science + Business Media

    Laia Pare

  85. Discovery and Functional Assessment of Gene Variants in the Vascular Endothelial Growth Factor Pathway

    Article • Human Mutation, November 2013, Wiley

    Laia Pare

  86. Intergenic polymorphisms in the amphiregulin gene region as biomarkers in metastatic colorectal cancer patients treated with anti-EGFR plus irinotecan

    Article • The Pharmacogenomics Journal, August 2013, Springer Science + Business Media

    Laia Pare

  87. The LCS6 polymorphism in the binding site of let-7 microRNA to the KRAS 3′-untranslated region

    Article • Pharmacogenetics and Genomics, March 2013, Wolters Kluwer Health

    Laia Pare

  88. Pharmacogenetic analysis in the treatment of Hodgkin lymphoma

    Article • Leukemia & Lymphoma, February 2013, Taylor & Francis

    Laia Pare

  89. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration

    Article • The Pharmacogenomics Journal, February 2012, Springer Science + Business Media

    Fernando Fernández-Bañares, Prof. Luis Rodrigo, Laia Pare

  90. Pharmacogenetic Study in Rectal Cancer Patients Treated With Preoperative Chemoradiotherapy: Polymorphisms in Thymidylate Synthase, Epidermal Growth Factor Receptor, GSTP1, and DNA Repair Genes

    Article • International Journal of Radiation Oncology*Biology*Physics, December 2011, Elsevier

    Laia Pare

  91. A genotype-directed phase I–IV dose-finding study of irinotecan in combination with fluorouracil/leucovorin as first-line treatment in advanced colorectal cancer

    Article • British Journal of Cancer, June 2011, Springer Science + Business Media

    Laia Pare

  92. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?

    Article • Cancer Science, August 2010, Wiley

    Laia Pare

  93. Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy

    Article • British Journal of Clinical Pharmacology, April 2010, Wiley

    Laia Pare

  94. Thymidylate synthase germline polymorphisms in rectal cancer patients treated with neoadjuvant chemoradiotherapy based on 5-fluorouracil

    Article • Journal of Cancer Research and Clinical Oncology, February 2010, Springer Science + Business Media

    Laia Pare

  95. Erratum: Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

    Article • British Journal of Cancer, April 2009, Springer Science + Business Media

    Laia Pare

  96. Impact of CYP2D6 polymorphisms in tamoxifen adjuvant breast cancer treatment

    Article • Breast Cancer Research and Treatment, February 2009, Springer Science + Business Media

    Laia Pare

  97. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy

    Article • British Journal of Cancer, September 2008, Springer Science + Business Media

    Laia Pare

  98. Methylenetetrahydrofolate Reductase Gene Polymorphisms: Genomic Predictors of Clinical Response to Fluoropyrimidine-Based Chemotherapy in Females

    Article • Journal of Clinical Oncology, July 2008, American Society of Clinical Oncology (ASCO)

    Laia Pare

  99. Irinotecan Pharmacogenetics: Influence of Pharmacodynamic Genes

    Article • Clinical Cancer Research, March 2008, American Association for Cancer Research (AACR)

    Laia Pare

  100. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin?

    Article • The Pharmacogenomics Journal, August 2007, Springer Science + Business Media

    Laia Pare

  101. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy

    Article • Anti-Cancer Drugs, August 2007, Wolters Kluwer Health

    Laia Pare